Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy

Abstract Pregnancy can increase the risk of latent tuberculosis infection (LTBI) progression to tuberculosis (TB) disease. Isoniazid (INH) is the preferred preventative treatment for LTBI in pregnancy. INH is mainly cleared by N‐acetyltransferase 2 (NAT2) but the pharmacokinetics (PK) of INH in diff...

Full description

Bibliographic Details
Main Authors: Ogochukwu U. Amaeze, Nina Isoherranen
Format: Article
Language:English
Published: Wiley 2023-11-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.13614
_version_ 1797627421072031744
author Ogochukwu U. Amaeze
Nina Isoherranen
author_facet Ogochukwu U. Amaeze
Nina Isoherranen
author_sort Ogochukwu U. Amaeze
collection DOAJ
description Abstract Pregnancy can increase the risk of latent tuberculosis infection (LTBI) progression to tuberculosis (TB) disease. Isoniazid (INH) is the preferred preventative treatment for LTBI in pregnancy. INH is mainly cleared by N‐acetyltransferase 2 (NAT2) but the pharmacokinetics (PK) of INH in different NAT2 phenotypes during pregnancy is not well characterized. To address this knowledge gap, we used physiologically based pharmacokinetic (PBPK) modeling to evaluate NAT2 phenotype‐specific effects of pregnancy on INH disposition. A whole‐body PBPK model for INH was developed and verified for non‐pregnant NAT2 fast (FA), intermediate (IA), and slow (SA) acetylators. Model predictive performance was assessed using a drug‐specific model acceptance criterion for mean plasma area under the curve (AUC) and peak plasma concentration (Cmax), and the absolute average fold error (AAFE) for individual plasma concentrations. The verified model was extended to simulate INH disposition during pregnancy in NAT2 SA, IA, and FA populations. A sensitivity analysis was conducted using the verified PBPK model and known changes in INH disposition during pregnancy to determine whether NAT2 activity changes during pregnancy or other INH clearance pathways are altered. This analysis suggested that NAT2 activity is unchanged while other INH clearance pathways increase by ~80% during pregnancy. The model was applied to explore the effect of pregnancy on INH disposition in two ethnic populations with different NAT2 phenotype distributions and with high TB burden. Our PBPK model can be used to predict INH disposition during pregnancy in diverse populations and expanded to other drugs cleared by NAT2 during pregnancy.
first_indexed 2024-03-11T10:23:54Z
format Article
id doaj.art-a5882e6e05c44aa7a97309f50c2691c1
institution Directory Open Access Journal
issn 1752-8054
1752-8062
language English
last_indexed 2024-03-11T10:23:54Z
publishDate 2023-11-01
publisher Wiley
record_format Article
series Clinical and Translational Science
spelling doaj.art-a5882e6e05c44aa7a97309f50c2691c12023-11-16T04:14:34ZengWileyClinical and Translational Science1752-80541752-80622023-11-0116112163217610.1111/cts.13614Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancyOgochukwu U. Amaeze0Nina Isoherranen1Department of Pharmaceutics University of Washington, School of Pharmacy Seattle Washington USADepartment of Pharmaceutics University of Washington, School of Pharmacy Seattle Washington USAAbstract Pregnancy can increase the risk of latent tuberculosis infection (LTBI) progression to tuberculosis (TB) disease. Isoniazid (INH) is the preferred preventative treatment for LTBI in pregnancy. INH is mainly cleared by N‐acetyltransferase 2 (NAT2) but the pharmacokinetics (PK) of INH in different NAT2 phenotypes during pregnancy is not well characterized. To address this knowledge gap, we used physiologically based pharmacokinetic (PBPK) modeling to evaluate NAT2 phenotype‐specific effects of pregnancy on INH disposition. A whole‐body PBPK model for INH was developed and verified for non‐pregnant NAT2 fast (FA), intermediate (IA), and slow (SA) acetylators. Model predictive performance was assessed using a drug‐specific model acceptance criterion for mean plasma area under the curve (AUC) and peak plasma concentration (Cmax), and the absolute average fold error (AAFE) for individual plasma concentrations. The verified model was extended to simulate INH disposition during pregnancy in NAT2 SA, IA, and FA populations. A sensitivity analysis was conducted using the verified PBPK model and known changes in INH disposition during pregnancy to determine whether NAT2 activity changes during pregnancy or other INH clearance pathways are altered. This analysis suggested that NAT2 activity is unchanged while other INH clearance pathways increase by ~80% during pregnancy. The model was applied to explore the effect of pregnancy on INH disposition in two ethnic populations with different NAT2 phenotype distributions and with high TB burden. Our PBPK model can be used to predict INH disposition during pregnancy in diverse populations and expanded to other drugs cleared by NAT2 during pregnancy.https://doi.org/10.1111/cts.13614
spellingShingle Ogochukwu U. Amaeze
Nina Isoherranen
Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy
Clinical and Translational Science
title Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy
title_full Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy
title_fullStr Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy
title_full_unstemmed Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy
title_short Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy
title_sort application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy
url https://doi.org/10.1111/cts.13614
work_keys_str_mv AT ogochukwuuamaeze applicationofaphysiologicallybasedpharmacokineticmodeltopredictisoniaziddispositionduringpregnancy
AT ninaisoherranen applicationofaphysiologicallybasedpharmacokineticmodeltopredictisoniaziddispositionduringpregnancy